Zydus Cadila receives final approval from USFDA for Meclizine Hydrochloride Tablets

Zydus Cadila has received final approval from the USFDA to market Meclizine Hydrochloride Tablets (US RLD: Antivert™ Tablets) in the strengths of 12.5 mg and 25 mg.

Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems. The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 292 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.367.1 as compared to the previous close of Rs. 360.7. The total number of shares traded during the day was 245319 in over 4487 trades.

The stock hit an intraday high of Rs. 368.7 and intraday low of 362. The net turnover during the day was Rs. 89793375.

Source : Equity Bulls

Keywords